Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy

Joseph Pikkel, Shimon Rumelt

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Purpose. Choroidal neovascularization (CNV) is a rare complication after laser photocoagulation for disorders such as central serous chorioretinopathy (CSC). Methods. We report 2 patients who developed CNV after laser treatment for persistent CSC and were treated by 3 1.25-mg intravitreal injections of bevacizumab in 1-month intervals. Results. In both patients, best-corrected visual acuity improved from 20/120 to 20/80 and from counting fingers at 3 feet to 20/100 over 12 months of follow-up. Conclusions. The favorable outcome suggests that intravitreal injection of bevacizumab may be beneficial for patients who develop CNV after laser photocoagulation. The favorable outcome may be related to the limited pathology.

Original languageEnglish
Pages (from-to)488-491
Number of pages4
JournalEuropean Journal of Ophthalmology
Volume22
Issue number3
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Argon laser photocoagulation
  • Bevacizumab
  • Central serous chorioretinopathy
  • Chorioretinal scar
  • Choroidal neovascularization
  • Intravitreal injection

Fingerprint

Dive into the research topics of 'Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy'. Together they form a unique fingerprint.

Cite this